title: Expression of Hepatocyte growth factor activator inhibitor type-1 (HAI-1) in prostate cancer.
abstract: BACKGROUND
  Hepatocyte growth factor activator inhibitor type-1 (HAI-1) inhibits hepatocyte growth factor activator and matriptase. In the present study it was investigated whether the expression of HAI-1 is associated with the progression of prostate cancer.
  
  
  METHODS
  The expression of HAI-1 was evaluated by immunohistochemistry (IHC) of samples from 51 patients with negative prostate biopsies and 75 patients with untreated prostate cancer. Furthermore, the expression of HAI-1 was evaluated in 24 patients with castration-resistant prostate cancer (CRPC), and the relationship between HAI-1 expression and the prostate-specific antigen (PSA) progression-free rate was investigated.
  
  
  RESULTS
  Expression of HAI-1 by IHC in patients with prostate cancer was significantly higher than in those with negative prostate biopsy. CRPC exhibited significantly lower HAI-1 expression than untreated metastatic prostate cancer. The PSA progression-free rate was worse in patients without HAI-1 expression than in those with positive HAI-1 expression.
  
  
  CONCLUSIONS
  It is suggested that HAI-1 may play an important role in the pathogenesis of CRPC.
authors: Department of Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
authors: Kenji
authors: K
authors: Yasuda
authors: Akira
authors: A
authors: Komiya
authors: Akihiko
authors: A
authors: Watanabe
authors: Akihiro
authors: A
authors: Morii
authors: Takeshi
authors: T
authors: Oya
authors: Osamu
authors: O
authors: Nagakawa
authors: Yasuyoshi
authors: Y
authors: Fujiuchi
authors: Hideki
authors: H
authors: Fuse
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D018450:Disease Progression; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm / Q000502:physiology; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D053491:Proteinase Inhibitory Proteins, Secretory / Q000096:biosynthesis*
chemical_list: D000726:Androgen Antagonists; D014408:Biomarkers, Tumor; D053491:Proteinase Inhibitory Proteins, Secretory; C109149:SPINT1 protein, human